Trial Profile
An open-label, randomised, parallel group study to evaluate pharmacokinetics, safety and tolerability of single-dose of Sacubitril/valsartan (LCZ696) in healthy Chinese male volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Mar 2016
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Adverse reactions; Pharmacokinetics
- 16 Mar 2016 New trial record
- 09 Mar 2016 Results published in the European Journal of Drug Metabolism and Pharmacokinetics.